

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)



(10) International Publication Number
WO 2023/278660 A3

(51) International Patent Classification:

C12N 15/12 (2006.01) C12N 9/22 (2006.01)
C12N 15/85 (2006.01) G01N 33/50 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/035666

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

30 June 2022 (30.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(88) Date of publication of the international search report:

23 February 2023 (23.02.2023)

(30) Priority Data:

63/218,221 02 July 2021 (02.07.2021) US
63/335,647 27 April 2022 (27.04.2022) US

(71) Applicant: THE BOARD OF REGENTS OF THE
UNIVERSITY OF TEXAS SYSTEM [US/US]; 210 West
7th Street, Austin, TX 78701 (US).

(72) Inventors: OLSON, Eric, N.; C/o Ut Southwestern Med-
ical Center, 5323 Harry Hines Blvd., Dallas, TX 75390
(US). BASSEL-DUBY, Rhonda; C/o Ut Southwestern
Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390
(US). NISHIYAMA, Takahiko; C/o Ut Southwestern
Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390
(US).

(74) Agent: SCHNEPP, Amanda, S.J.; Parker Highlander
PLLC, 1120 S. Capital Of Texas Highway, Bldg. One, Suite
200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: GENOMIC EDITING OF RBM20 MUTATIONS

(57) Abstract: Disclosures herein are directed to compositions comprising single guide RNA (sgRNA) designed for a CRISPR/Cas9 system and method of using thereof for preventing, ameliorating or treating one or more cardiomyopathies. For example, provided herein are composition and methods for the correction of dilated cardiomyopathy by precise genomic editing of RBM20 mutations in human cells and mice.

WO 2023/278660 A3